Chiesi Tackles Carbon Footprint Of Inhalers
Inks Propellant Deal With Koura
The Italian firm has laid out its ambitious plan to introduce the first carbon minimal pressurized metered dose inhaler for asthma and COPD by 2025 and secured supply of a new environmentally friendly propellant.
You may also be interested in...
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.
The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.